[{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Cocrystal Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Cocrystal Pharma \/ Cocrystal Pharma"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Antiviral drugs","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Cocrystal Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Cocrystal Pharma"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Antiviral therapy","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"CC-31244","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CDI-45205","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"CDI-988","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cocrystal Pharma \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"CDI-873","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"4","companyTruncated":"Cocrystal Pharma \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CC-42344","moa":"PB2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CC-42344","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CC-42344","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Phillip Frost","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"CC-42344","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Phillip Frost","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Phillip Frost"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CDI-988","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CDI-988","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CC-42344","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CC-42344","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CC-42344","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CC-42344","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CC-42344","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CDI-988","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CDI-988","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CC-42344","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cocrystal Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Cocrystal Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CDI-988","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Cocrystal Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cocrystal Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cocrystal Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Cocrystal Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : CDI-988, a novel, oral, broad-spectrum 3CL protease inhibitor, is being developed as a potential treatment for norovirus and coronavirus infections.

Product Name : CDI-988

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

January 08, 2025

Lead Product(s) : CDI-988

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

02

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : CC-42344 is a novel, oral broad-spectrum PB2 inhibitor, which is being evaluated for the treatment of avian influenza A H5N1 subtype.

Product Name : CC-42344

Product Type : Small molecule

Upfront Cash : Not Applicable

December 31, 2024

Lead Product(s) : CC-42344

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : CDI-988, a novel, oral, broad-spectrum 3CL protease inhibitor, receives HREC approval to conduct a Phase 1 study for the potential treatment for COVID-19.

Product Name : CDI-988

Product Type : Small molecule

Upfront Cash : Not Applicable

September 26, 2024

Lead Product(s) : CDI-988

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : CDI-988, a novel, oral, broad-spectrum 3CL protease inhibitor, receives HREC approval to conduct a Phase 1 study for the potential treatment for COVID-19.

Product Name : CDI-988

Product Type : Small molecule

Upfront Cash : Not Applicable

July 18, 2024

Lead Product(s) : CDI-988

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : CC-42344 is a novel, oral broad-spectrum PB2 inhibitor, which is being evaluated for the treatment of avian influenza A H5N1 subtype.

Product Name : CC-42344

Product Type : Small molecule

Upfront Cash : Not Applicable

June 20, 2024

Lead Product(s) : CC-42344

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : CC-42344 is a novel, broad-spectrum PB2 inhibitor, investigational antiviral candidate, which is being evaluated for the treatment of pandemic and seasonal influenza A.

Product Name : CC-42344

Product Type : Small molecule

Upfront Cash : Not Applicable

May 01, 2024

Lead Product(s) : CC-42344

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

07

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : CC-42344 is a novel, broad-spectrum PB2 inhibitor, investigational antiviral candidate, which is being evaluated for the treatment of pandemic and seasonal influenza A.

Product Name : CC-42344

Product Type : Small molecule

Upfront Cash : Not Applicable

March 19, 2024

Lead Product(s) : CC-42344

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : CC-42344 is a novel, broad-spectrum PB2 inhibitor, investigational antiviral candidate, which is being evaluated for the treatment of pandemic and seasonal influenza A.

Product Name : CC-42344

Product Type : Small molecule

Upfront Cash : Not Applicable

December 06, 2023

Lead Product(s) : CC-42344

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

09

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : CC-42344 is a oral small molecule PB2 inhibitor which is being evaluated for the treatment of pandemic and seasonal influenza A in phase 2 clinical trials.

Product Name : CC-42344

Product Type : Small molecule

Upfront Cash : Not Applicable

October 31, 2023

Lead Product(s) : CC-42344

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

10

Biotech Digital Meet
Not Confirmed
Biotech Digital Meet
Not Confirmed

Details : CDI-988, a novel, oral, broad-spectrum 3CL protease inhibitor, receives HREC approval to conduct a Phase 1 study for the potential treatment for COVID-19.

Product Name : CDI-988

Product Type : Small molecule

Upfront Cash : Not Applicable

September 28, 2023

Lead Product(s) : CDI-988

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank